Literature DB >> 34718501

Surgical treatment for post-infarction papillary muscle rupture: a multicentre study.

Giulio Massimi1, Daniele Ronco1,2, Michele De Bonis3, Mariusz Kowalewski1,4, Francesco Formica5,6, Claudio Francesco Russo7, Sandro Sponga8, Igor Vendramin8, Giosuè Falcetta9, Theodor Fischlein10, Giovanni Troise11, Cinzia Trumello3, Guglielmo Actis Dato12, Massimiliano Carrozzini7, Shabir Hussain Shah13, Valeria Lo Coco1, Emmanuel Villa11, Roberto Scrofani14, Federica Torchio2, Carlo Antona14, Jurij Matija Kalisnik10, Stefano D'Alessandro5, Matteo Pettinari15, Peyman Sardari Nia1, Vittoria Lodo12, Andrea Colli9, Arjang Ruhparwar16, Matthias Thielmann16, Bart Meyns17, Fareed A Khouqeer18, Carlo Fino19, Caterina Simon19, Adam Kowalowka20, Marek A Deja20, Cesare Beghi2, Matteo Matteucci1,2, Roberto Lorusso1,21.   

Abstract

OBJECTIVES: Papillary muscle rupture (PMR) is a rare but potentially fatal complication of acute myocardial infarction. The aim of this study was to analyse the patient characteristics and early outcomes of the surgical management of post-infarction PMR from an international multicentre registry.
METHODS: Patients underwent surgery for post-infarction PMR between 2001 through 2019 were retrieved from database of the CAUTION study. The primary end point was in-hospital mortality.
RESULTS: A total of 214 patients were included with a mean age of 66.9 (standard deviation: 10.5) years. The posteromedial papillary muscle was the most frequent rupture location (71.9%); the rupture was complete in 67.3% of patients. Mitral valve replacement was performed in 82.7% of cases. One hundred twenty-two patients (57%) had concomitant coronary artery bypass grafting. In-hospital mortality was 24.8%. Temporal trends revealed no apparent improvement in in-hospital mortality during the study period. Multivariable analysis showed that preoperative chronic kidney disfunction [odds ratio (OR): 2.62, 95% confidence interval (CI): 1.07-6.45, P = 0.036], cardiac arrest (OR: 3.99, 95% CI: 1.02-15.61, P = 0.046) and cardiopulmonary bypass duration (OR: 1.01, 95% CI: 1.00-1.02, P = 0.04) were independently associated with an increased risk of in-hospital death, whereas concomitant coronary artery bypass grafting was identified as an independent predictor of early survival (OR: 0.38, 95% CI: 0.16-0.92, P = 0.031).
CONCLUSIONS: Surgical treatment for post-infarction PMR carries a high in-hospital mortality rate, which did not improve during the study period. Because concomitant coronary artery bypass grafting confers a survival benefit, this additional procedure should be performed, whenever possible, in an attempt to improve the outcome. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov: NCT03848429.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Acute mitral regurgitation; Mitral valve surgery; Papillary muscle rupture

Mesh:

Year:  2022        PMID: 34718501     DOI: 10.1093/ejcts/ezab469

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

Review 1.  Mitral valve repair in papillary muscle rupture.

Authors:  Umar Imran Hamid; Rezan Aksoy; Peyman Sardari Nia
Journal:  Ann Cardiothorac Surg       Date:  2022-05

Review 2.  Operative strategies for acute mitral regurgitation as a mechanical complication of myocardial infarction.

Authors:  Giulio Massimi; Matteo Matteucci; Mariusz Kowalewski; Daniele Ronco; Giovanni Chiarini; Maria Elena De Piero; Valeria Lo Coco; Jos G Maessen; Cesare Beghi; Roberto Lorusso
Journal:  Ann Cardiothorac Surg       Date:  2022-05

3.  Disruptive technologies in mitral modelling-a riot of innovation.

Authors:  Apurva H Bharucha; Mehdi Eskandari; Olaf Wendler; Max Baghai
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-05-02

4.  A Hybrid Intervention for Post-infarction Papillary Muscle Rupture with Severe Mitral Regurgitation: A Case Report.

Authors:  Kosuke Nakamae; Takashi Oshitomi; Hideyuki Uesugi
Journal:  J Chest Surg       Date:  2022-06-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.